How do I get my loved one into treatment?

Start with a calm, caring conversation expressing specific concerns. Offer to help research treatment options. Consider the CRAFT method (Community Reinforcement and Family Training), which has a 64-74% success rate. A professional intervention is another option if they refuse.

Should I do an intervention?

Professional interventions have an 80-90% success rate in getting the person to accept treatment. Consider an intervention when your loved one denies the problem, has refused repeated suggestions to get help, and consequences are escalating.

2026 mental health

Ozempic and addiction: What we know about GLP-1 medications and substance use

Published December 2, 2025 · 8 min read · Updated April 2026

Last medically reviewed: April 2026

Reviewed for accuracy by licensed clinical professionals. Editorial process.

One of the most unexpected developments in addiction medicine has been the growing body of anecdotal and early clinical evidence suggesting that GLP-1 receptor agonists — medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) — may reduce cravings for alcohol, nicotine, and other substances.

What the research shows

GLP-1 receptors are present not only in the gut and pancreas but also in the brain's reward centers — the same regions implicated in addiction. Animal studies have consistently shown that GLP-1 agonists reduce alcohol consumption, nicotine self-administration, and cocaine-seeking behavior. In humans, anecdotal reports from patients on Ozempic for diabetes or weight loss describe spontaneous reduction in alcohol consumption, reduced interest in smoking, and decreased cravings for addictive substances. Early clinical trials specifically studying semaglutide for alcohol use disorder are underway, with preliminary results expected soon.

What it doesn't mean

It is far too early to recommend GLP-1 medications as an addiction treatment. The human evidence is primarily anecdotal, clinical trials are still in early phases, the mechanism of action for addiction reduction is not fully understood, side effects (nausea, gastroparesis, pancreatitis risk) are significant, and the medications are expensive ($800-$1,300/month without insurance). No addiction medicine organization currently recommends GLP-1 agonists for substance use disorders. Anyone considering these medications should do so under medical supervision for their approved indications.

Why it matters for the future

If clinical trials confirm the anti-addiction effects, GLP-1 medications could represent an entirely new pharmacological approach to addiction — one that works on the reward circuitry itself rather than simply blocking or replacing the substance. This is a space worth watching, and we will update this article as new research is published.